351 related articles for article (PubMed ID: 36044102)
1. Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals.
Al-Kuraishy HM; Batiha GE; Faidah H; Al-Gareeb AI; Saad HM; Simal-Gandara J
Inflammopharmacology; 2022 Dec; 30(6):2017-2026. PubMed ID: 36044102
[TBL] [Abstract][Full Text] [Related]
2. Role of pirfenidone in TGF-β pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective.
Hamidi SH; Kadamboor Veethil S; Hamidi SH
Pharmacol Rep; 2021 Jun; 73(3):712-727. PubMed ID: 33880743
[TBL] [Abstract][Full Text] [Related]
3. Ovatodiolide inhibits SARS-CoV-2 replication and ameliorates pulmonary fibrosis through suppression of the TGF-β/TβRs signaling pathway.
Chiou WC; Huang GJ; Chang TY; Hsia TL; Yu HY; Lo JM; Fu PK; Huang C
Biomed Pharmacother; 2023 May; 161():114481. PubMed ID: 36906971
[TBL] [Abstract][Full Text] [Related]
4. COVID-19: Immunohistochemical Analysis of TGF-β Signaling Pathways in Pulmonary Fibrosis.
Vaz de Paula CB; Nagashima S; Liberalesso V; Collete M; da Silva FPG; Oricil AGG; Barbosa GS; da Silva GVC; Wiedmer DB; da Silva Dezidério F; Noronha L
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008594
[TBL] [Abstract][Full Text] [Related]
5. Nitazoxanide and COVID-19: A review.
Al-Kuraishy HM; Al-Gareeb AI; Elekhnawy E; Batiha GE
Mol Biol Rep; 2022 Nov; 49(11):11169-11176. PubMed ID: 36094778
[TBL] [Abstract][Full Text] [Related]
6. ISM1 suppresses LPS-induced acute lung injury and post-injury lung fibrosis in mice.
Nguyen N; Xu S; Lam TYW; Liao W; Wong WSF; Ge R
Mol Med; 2022 Jun; 28(1):72. PubMed ID: 35752760
[TBL] [Abstract][Full Text] [Related]
7. Ursolic acid and SARS-CoV-2 infection: a new horizon and perspective.
Al-Kuraishy HM; Al-Gareeb AI; Negm WA; Alexiou A; Batiha GE
Inflammopharmacology; 2022 Oct; 30(5):1493-1501. PubMed ID: 35922738
[TBL] [Abstract][Full Text] [Related]
8. Post-COVID-19 Pulmonary Fibrosis.
Mohammadi A; Balan I; Yadav S; Matos WF; Kharawala A; Gaddam M; Sarabia N; Koneru SC; Suddapalli SK; Marzban S
Cureus; 2022 Mar; 14(3):e22770. PubMed ID: 35371880
[TBL] [Abstract][Full Text] [Related]
9. A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19.
Sahebnasagh A; Mojtahedzadeh M; Najmeddin F; Najafi A; Safdari M; Rezai Ghaleno H; Habtemariam S; Berindan-Neagoe I; Nabavi SM
Arch Med Res; 2020 Oct; 51(7):631-635. PubMed ID: 32863034
[TBL] [Abstract][Full Text] [Related]
10. Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1.
Jin J; Togo S; Kadoya K; Tulafu M; Namba Y; Iwai M; Watanabe J; Nagahama K; Okabe T; Hidayat M; Kodama Y; Kitamura H; Ogura T; Kitamura N; Ikeo K; Sasaki S; Tominaga S; Takahashi K
Respir Res; 2019 Jun; 20(1):119. PubMed ID: 31185973
[TBL] [Abstract][Full Text] [Related]
11. Lung recovery with prolonged ECMO following fibrotic COVID-19 acute respiratory distress syndrome.
Kazi AW; Summer R; Sundaram B; George G
Am J Med Sci; 2023 Mar; 365(3):307-312. PubMed ID: 36535539
[TBL] [Abstract][Full Text] [Related]
12. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis.
Liu F; Lagares D; Choi KM; Stopfer L; Marinković A; Vrbanac V; Probst CK; Hiemer SE; Sisson TH; Horowitz JC; Rosas IO; Fredenburgh LE; Feghali-Bostwick C; Varelas X; Tager AM; Tschumperlin DJ
Am J Physiol Lung Cell Mol Physiol; 2015 Feb; 308(4):L344-57. PubMed ID: 25502501
[TBL] [Abstract][Full Text] [Related]
13. The role of berberine in Covid-19: potential adjunct therapy.
Babalghith AO; Al-Kuraishy HM; Al-Gareeb AI; De Waard M; Al-Hamash SM; Jean-Marc S; Negm WA; Batiha GE
Inflammopharmacology; 2022 Dec; 30(6):2003-2016. PubMed ID: 36183284
[TBL] [Abstract][Full Text] [Related]
14. Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt/GSK-3β/β-catenin and TGF-β1/Smad2/3 signaling pathways.
Lv Q; Wang J; Xu C; Huang X; Ruan Z; Dai Y
Mol Med; 2020 May; 26(1):49. PubMed ID: 32448163
[TBL] [Abstract][Full Text] [Related]
15. Autophagy Augmentation to Alleviate Immune Response Dysfunction, and Resolve Respiratory and COVID-19 Exacerbations.
Pehote G; Vij N
Cells; 2020 Aug; 9(9):. PubMed ID: 32847034
[TBL] [Abstract][Full Text] [Related]
16. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
17. High-mobility group box 1 (HMGB1) in COVID-19: extrapolation of dangerous liaisons.
Al-Kuraishy HM; Al-Gareeb AI; Alkazmi L; Habotta OA; Batiha GE
Inflammopharmacology; 2022 Jun; 30(3):811-820. PubMed ID: 35471628
[TBL] [Abstract][Full Text] [Related]
18. Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells.
Molina-Molina M; Machahua-Huamani C; Vicens-Zygmunt V; Llatjós R; Escobar I; Sala-Llinas E; Luburich-Hernaiz P; Dorca J; Montes-Worboys A
BMC Pulm Med; 2018 Apr; 18(1):63. PubMed ID: 29703175
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary fibrosis: A short- or long-term sequelae of severe COVID-19?
Zheng Z; Peng F; Zhou Y
Chin Med J Pulm Crit Care Med; 2023 Jun; 1(2):77-83. PubMed ID: 37388822
[TBL] [Abstract][Full Text] [Related]
20. Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy.
Kurita Y; Araya J; Minagawa S; Hara H; Ichikawa A; Saito N; Kadota T; Tsubouchi K; Sato N; Yoshida M; Kobayashi K; Ito S; Fujita Y; Utsumi H; Yanagisawa H; Hashimoto M; Wakui H; Yoshii Y; Ishikawa T; Numata T; Kaneko Y; Asano H; Yamashita M; Odaka M; Morikawa T; Nakayama K; Kuwano K
Respir Res; 2017 Jun; 18(1):114. PubMed ID: 28577568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
